FDA approves Agios' IDH1 inhibitor for AML

FDA approved Tibsovo ivosidenib (formerly AG-120) from Agios Pharmaceuticals Inc. (NASDAQ:AGIO) on Friday to treat relapsed or refractory acute myelogenous

Read the full 208 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE